2024中国药企出海报告

EmpowerBiopharmaInnovationAccelerateDecision-making Foundedin2015,Pharmcubestrivestoreconstructpharmaceuticaldata,bridgetheinformationgap,andthoroughlyempowerinnovation.Byleveraging Wealsoprovideyouwithmediaandconsultingservicesthatfacilitateyour strategicplanninganddecision-makingandpromotetheinnovationand transformationofthepharmaceuticalindustry. OurIndustryInfluence Ourtrustworthydataandconstantly-improvingservicehavewonclient'sheart. WeAreGrowing Weteamupwithtoptalents.Over56%masterorPh.Dholders,andmorethan60%topuniversitygraduates(suchasPekingUniversity,Tsinghua NextBiopharm™--Timely,accurateandreliable intelligenceonglobalnewdrugs "IntroducingNextBiopharm™,acutting-edgedatabasemeticulouslycraftedandlaunchedbyPharmcube,designedspecificallytospotlight globalnewdrugswithunparalleledcoverageintheChinesemarket. This platformseamlesslyintegratesandstandardizesawealthofinformation,includingpatents,literature,clinicaltrials,news,deals,andmarketingdata,providingacomprehensiveoverviewofeverynovel iDealsVDREmpowers75%ofOut-licensingDeals AsBDtransactionsbecomemorefrequentandactive,thevirtualdataroom(VDR)becomesanindispensable iDealsSolutionsprovidesacomprehensiveVDRsolution,whichisasapowerfulassistant Itsimplifiestheprocessofsharingandmanaging Itsfinancial-gradedocumentsecuritysolutionensuresthatthecompany's confidential EmpowerstheentireprocessofcorporateBDtransactions,includingprotectingdatasecurity, Contact Us PharmcubeContactus： lAboutProduct/Servicedaisiwei@pharmcube.com sanyunan@pharmcube.comAfter-Sales zhangxiaoyi@pharmcube.comForMediaCollaboration iDealsContactus：Trialrequest: CONTENTS PARTONE Followthetrendofthetimes FactorscompellingChinesepharmaceuticalcompaniestogoglobal Insightsontransactions PARTTHREE Data-baseddecision-making Applicationofdatainscreeningoverseasopportunities PARTONE Factors Compelling Chinese Pharmaceutical IntensecompetitionwithintheChinesemarketisdriving Inrecentyears,Chinese Themedicalinsurancepaymentreformandrestrictedhospitalaccesshavesqueezedtheprofitmarginsofinnovativedrugs. Facedwithfinancialchallenges,manycompaniesarechoosing Thepharmaceuticalindustryis experiencing downwardpressure,withmostcompanieshavingdifficultyinfundingand With growing strength in R&D of new drugs,Chinese AsmoretalentsreturntotheChinesemarketandinnovationfactorsaccumulate,China-originatedbiotechsaresteppinginto Government policies encourage Chinesecompaniesto China'spharmaceuticalindustryhasenteredanewstageofdevelopment.Inrecentyears,nationalregulatorypolicieshave Inrecentyears,Chinesepharmaceuticalcompanieshave ThenumberofInvestigationalNewDrugApplication Inrecentyears,Chinesecompanieshaveexhibitedagreatercapability in R&D of innovative drugs.The number of Thehistoricalnumberofbreakthrough Chinaranksthesecondintheworld,aftertheU.S.,intermsofthenumberofmilestonepublications,surpassingGermany, Note:Breakthroughtranslationalmedicalresearch Numberofpivotalclinicaltrials Inthisrespect,ChinesepharmaceuticalcompaniesareclosingthegapwiththeircounterpartsintheU.S.,showing conductedbypharmaceutical GovernmentpoliciessupportChinesepharmaceutical In1990,regulatoryauthoritiesandinternationalassociationsintheEU,U.S.,andJapancreatedtheInternationalCouncilfor Beginning:Initialexplorationofthe InJune2017,theformerChinaFoodanddrugsAdministration(CFDA)joined ICH,marking the official start of China's GuidingChinesecompaniestoalignwithinternationalstandardsinthedesignofclinical NumberofMRCTconductedbyChinese Developing:Proactivedevelopmenttowards Central Duringthe13thFive-YearPlan(FYP)period,China'spharmaceuticalindustryunderwentagradualshifttowardshigheraddedvalue.Duringthe14thFYPperiod, Local Expandingtheglobalpresencehasbeenakeyfocusof PharmaceuticalcompaniesencounterdevelopmentobstaclesintheChinesemarket,primarilyconsistingofa Medicalinsurance Ittakesyearsforanewlylaunched Theaveragetimeforanewlyapproveddrugstobecoveredby Pricereductionasa Medicalinsurancenegotiationshaveappliedsignificantpressure Source:Researchandanalysisby Hospitalaccessibility Newdrugsallowedforuseinpublicmedical Numberofgradedhospitals Numberofnewdrugsallowedinto Underthedualpressureofproductpricinganddomesticcompetition,Chinesepharmaceuticalcompaniesare Annualexpenditurefortreatmentwith UnlikeintheU.S.wheredrugsarepricedbasedontheirvalue,drugsinChinaaregenerallypricedbasedontheircost, China and the U.S.have contrasting procedures forauthorizingaccessofnewdrugstohospitals.TheChinese Differentproceduresfor accessinghospitalsin Theglobalmarkettakesprecedenceoverallothermarkets.Thus,it isimperativefor Chinese pharmaceutical companies to Global pharmaceuticalmarketsizeand Source:ResearchandanalysisbyPharmcube; Theoverseasmarkethasbecomethemainsourceofsalesfor SalesofBeiGene'sZanubrutinibin Fundinghasbecomeincreasinglytoughinrecentyears,somostpharmaceuticalcompaniesarelookingtoimprove In2020,thepharmaceuticalindustrybegantoexperiencefundingchallenge.Chinesecomp